Pramlintide is a short-acting amylin analog that lacks calcitonin receptor activity and requires frequent dosing
No human studies have confirmed this effect
After Peptide Sciences shut down in March 2026, Pepta Labs is one of the verified vendors still operating with full third-party testing
The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management
Complementary Topicals Pairs well with other active ingredients like retinoids, vitamin C, and hyaluronic acid for enhanced anti-aging and skin-repair effects
10.1016/j.smim.2019.04.003 28 Santos BrunoF.InsG.Martel PauloJ.FerreiraB